FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313857591> ?p ?o ?g. }

• W4313857591 abstract "Isoniazid pharmacokinetics are not yet well-described during once weekly, high-dose administrations with rifapentine (3HP) for latent tuberculosis infection (LTBI). Fewer data describe 3HP with dolutegravir-based antiretroviral therapy for the treatment of human immunodeficiency virus (HIV). The only prior report of 3HP with dolutegravir reported elevated isoniazid exposures. We measured the plasma isoniazid levels in 30 adults receiving 3HP and dolutegravir for the treatment of LTBI and HIV. The patients were genotyped to determine NAT2 acetylator status, and a population PK model was estimated by nonlinear mixed-effects modeling. The results were compared to previously reported data describing 3HP with dolutegravir, 3HP alone, and isoniazid with neither dolutegravir nor rifapentine. The isoniazid concentrations were adequately described by a one compartment model with a transit compartment absorption process. The isoniazid clearance for slow (8.33 L/h) and intermediate (12 L/h) acetylators were similar to previously reported values. Rapid acetylators (N = 4) had clearance similar to those of intermediate acetylators and much slower than typically reported, but the small sample size was limiting. The absorption rate was lower than usual, likely due to the coadministration with food, and it was faster among individuals with a low body weight. Low-body weight participants were also observed to have greater oral bioavailability. The isoniazid exposures were consistent with, or greater than, the previously reported elevated concentrations among individuals receiving 3HP and dolutegravir. The concentrations were substantially greater than those presented in previous reports among individuals receiving 3HP or isoniazid without rifapentine or dolutegravir. We discuss the implications of these findings and the possibility of a drug-drug interaction that is mediated by cellular transport. (This study has been registered at ClinicalTrials.gov under identifier NCT03435146 and has South African National Clinical Trial Registration no. DOH-27-1217-5770.)." @default.
• W4313857591 created "2023-01-10" @default.
• W4313857591 creator A5007514947 @default.
• W4313857591 creator A5015504359 @default.
• W4313857591 creator A5032195304 @default.
• W4313857591 creator A5062664219 @default.
• W4313857591 creator A5071106707 @default.
• W4313857591 creator A5071742798 @default.
• W4313857591 creator A5082007029 @default.
• W4313857591 creator A5087491613 @default.
• W4313857591 date "2023-02-16" @default.
• W4313857591 modified "2023-09-26" @default.
• W4313857591 title "High Isoniazid Exposures When Administered with Rifapentine Once Weekly for Latent Tuberculosis in Individuals with Human Immunodeficiency Virus" @default.
• W4313857591 cites W1489900818 @default.
• W4313857591 cites W1576868446 @default.
• W4313857591 cites W2000542384 @default.
• W4313857591 cites W2003562401 @default.
• W4313857591 cites W2027951201 @default.
• W4313857591 cites W2085120686 @default.
• W4313857591 cites W2093591755 @default.
• W4313857591 cites W2101398264 @default.
• W4313857591 cites W2106892252 @default.
• W4313857591 cites W2120416054 @default.
• W4313857591 cites W2120725688 @default.
• W4313857591 cites W2146348626 @default.
• W4313857591 cites W2147715826 @default.
• W4313857591 cites W2148232746 @default.
• W4313857591 cites W2267486699 @default.
• W4313857591 cites W2287214128 @default.
• W4313857591 cites W2318240367 @default.
• W4313857591 cites W2465612624 @default.
• W4313857591 cites W2533230523 @default.
• W4313857591 cites W2621456888 @default.
• W4313857591 cites W2789372778 @default.
• W4313857591 cites W2807695141 @default.
• W4313857591 cites W2883254266 @default.
• W4313857591 cites W2890636891 @default.
• W4313857591 cites W2903289257 @default.
• W4313857591 cites W2914237926 @default.
• W4313857591 cites W2940519666 @default.
• W4313857591 cites W2948326298 @default.
• W4313857591 cites W2974522977 @default.
• W4313857591 cites W3004794654 @default.
• W4313857591 cites W3014021031 @default.
• W4313857591 cites W3086131504 @default.
• W4313857591 cites W3090880167 @default.
• W4313857591 cites W3092506295 @default.
• W4313857591 cites W3138845742 @default.
• W4313857591 cites W3178348975 @default.
• W4313857591 cites W3184783547 @default.
• W4313857591 cites W4295754778 @default.
• W4313857591 doi "https://doi.org/10.1128/aac.01297-22" @default.
• W4313857591 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36622148" @default.
• W4313857591 hasPublicationYear "2023" @default.
• W4313857591 type Work @default.
• W4313857591 citedByCount "2" @default.
• W4313857591 countsByYear W43138575912023 @default.
• W4313857591 crossrefType "journal-article" @default.
• W4313857591 hasAuthorship W4313857591A5007514947 @default.
• W4313857591 hasAuthorship W4313857591A5015504359 @default.
• W4313857591 hasAuthorship W4313857591A5032195304 @default.
• W4313857591 hasAuthorship W4313857591A5062664219 @default.
• W4313857591 hasAuthorship W4313857591A5071106707 @default.
• W4313857591 hasAuthorship W4313857591A5071742798 @default.
• W4313857591 hasAuthorship W4313857591A5082007029 @default.
• W4313857591 hasAuthorship W4313857591A5087491613 @default.
• W4313857591 hasBestOaLocation W43138575912 @default.
• W4313857591 hasConcept C112705442 @default.
• W4313857591 hasConcept C126322002 @default.
• W4313857591 hasConcept C142462285 @default.
• W4313857591 hasConcept C142724271 @default.
• W4313857591 hasConcept C159047783 @default.
• W4313857591 hasConcept C2776967927 @default.
• W4313857591 hasConcept C2776991065 @default.
• W4313857591 hasConcept C2777975735 @default.
• W4313857591 hasConcept C2779502633 @default.
• W4313857591 hasConcept C2779806340 @default.
• W4313857591 hasConcept C2781069245 @default.
• W4313857591 hasConcept C2908647359 @default.
• W4313857591 hasConcept C2993143319 @default.
• W4313857591 hasConcept C3013748606 @default.
• W4313857591 hasConcept C71924100 @default.
• W4313857591 hasConcept C98274493 @default.
• W4313857591 hasConcept C99454951 @default.
• W4313857591 hasConceptScore W4313857591C112705442 @default.
• W4313857591 hasConceptScore W4313857591C126322002 @default.
• W4313857591 hasConceptScore W4313857591C142462285 @default.
• W4313857591 hasConceptScore W4313857591C142724271 @default.
• W4313857591 hasConceptScore W4313857591C159047783 @default.
• W4313857591 hasConceptScore W4313857591C2776967927 @default.
• W4313857591 hasConceptScore W4313857591C2776991065 @default.
• W4313857591 hasConceptScore W4313857591C2777975735 @default.
• W4313857591 hasConceptScore W4313857591C2779502633 @default.
• W4313857591 hasConceptScore W4313857591C2779806340 @default.
• W4313857591 hasConceptScore W4313857591C2781069245 @default.
• W4313857591 hasConceptScore W4313857591C2908647359 @default.
• W4313857591 hasConceptScore W4313857591C2993143319 @default.
• W4313857591 hasConceptScore W4313857591C3013748606 @default.
• W4313857591 hasConceptScore W4313857591C71924100 @default.
• W4313857591 hasConceptScore W4313857591C98274493 @default.

• next